Sep032021

Novartis today announced that following an interim analysis of data from the CIRRUS-1study，adecision has been taken to discontinue the trial

  • The analysis indicated that CFZ533（iscalimab）-based treatment is less efficicacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant。Both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies（induction therapy，mycophenolate and corticosteroids）。
  • Study of CFZ533in liver transplant continues，as do studies exploring CFZ533as a potential treatment in other conditions，such as hidradenitis suppurativa and Sjögren’s syndrome。

Novartis is continuing to review the data from the CIRRUS-1study.Once complete，results will be shared with the broader scientific community。

Disclaimer:

This investor update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.Forward-looking statements can generally be identified by words such as“potential，”“can，”“will，”“plan，”“may，”“could，”“would，”“expect，”“ipate”“look forward，”“believe，”“committed，”“investigational，”“pipeline，”“launch，”or similar terms，按express or implied discussions regarding potential marketing approvals，new indications or labeling for the investigational or approved products described in this media update， orregarding potential future revenues from such products.You should not place undue reliance on these statements.Such forward-looking statements are based on our current beliefs and expectations regarding future events， and are subject to significant known and unknown risks and uncertainties.Should one or more of these risks or uncertainties materialize，or should underlying assumptions prove incorrect， actual results may vary materially from those set forth in the forward-looking statements.There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market， or at any particular time.Nor can there be any guarantee that such products will be commercially successful in the future.In particular，our expectations regarding such products could be affected by，among other things，the uncertainherent in research and development， including clinical trial results and additional analysis of existing clinical data；regulatory actions or delays or government regulation generally；global trends toward health care cost containment，including government， 城市公共公共交通和reimbursement pressures and requirement为increased pricing transparency， including the effect of and efforts to mitigate pandemic diseases such as COVID-19；safety，quality，data integrity or manufacturing issues；potential or actual data security and data privacy breaches，or disruptions of our information technology systems， and other risks and factors referred to in Novartis AG’s current Form20-F on file with the US Securities and Exchange Commission.Novartis is is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as date as suformation of， future events or otherwise。